Upadacitinib shows promise in phase 3 study in psoriatic arthritis

The JAK inhibitor upadacitinib was more effective than placebo and as or more effective than adalimumab in a randomised controlled trial of patients with psoriatic arthritis who had failed to respond to nonbiologic disease-modifying antirheumatic drugs (DMARDs). The efficacy, however, did come with some increase in toxicity as well. One previous trial in rheumatoid arthritis ...

Already a member?

Login to keep reading.

© 2022 the limbic